NEW YORK ─ ArcherDx announced on Thursday a collaboration with New York-based biopharmaceutical firm Bristol Myers Squibb to use the genomic analysis company's personalized cancer monitoring (PCM) assays for minimal residual disease (MRD) detection in cancer patients treated with immunotherapy.
ArcherDx said the firms will evaluate clinical samples from cancer-patient cohorts to advance MRD detection or ctDNA clearance to potentially inform future therapy selection or optimization, or both.
Financial and other terms of the collaboration were not disclosed.